Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.


  • Further studies are needed to support use of bone marrow transplant (BMT) in high-risk NHL patients
  • Treatment of choice for patients with aggressive recurrent NHL
  • Studies show improved survival (20-40% long-term disease-free rate) in high-risk patients
  • Autologous stem cell rescue therapy (ASCRT) after high-dose therapy (HDT) is recommended in the following:
    • Consolidation after aggressive treatment of MCL
    • 2nd-line or extended dosing of FL and MZL
  • Allogeneic hematopoietic cell transplant may be used in the 2nd-line consolidation treatment of FL, MZL and MCL 
  • May be considered in patients with indolent recurrent NHL, and aggressive noncontiguous stage II/III/IV NHL
    • Studies show an increase in the progression-free survival rate of patients given SCT as compared to those given chemotherapy alone
Editor's Recommendations
Special Reports